tralokinumab vs Zumilokibart
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: IL-13 · full Atopic Dermatitis pipeline
tralokinumab · Adbry
Marketed by LEO Pharma and partners
NCT05958407 · Phase 3 · completed
The 235 participants were randomized 2:1 to tralokinumab or placebo and the initial 16-week comparison was double-blinded. The primary clinical endpoint—an Investigator’s Global Assessment score of 0 or 1 at Week 16—was met, occurring in 40.0% of the tralokinumab group versus 10.6% of the placebo group (p<.001).
Next expected readout: June 2030 · NCT07352566 (registry estimate)
Reported efficacy
Percentage of Participants With IGA-AHE Score of 0 (Clear) or 1 (Almost Clear) (At Week 16): Percentage of Participants With IGA-AHE Score of 0 (Clear) or 1 (Almost Clear) (At Week 16): Tralokinumab 40% (95% CI 31.3 to 49.4) vs Placebo 10.6% (95% CI 5 to 20.9) (met)
Result source: NCT05958407
Zumilokibart
Developed by Apogee Therapeutics and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: November 2026 · NCT06395948 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Atopic Dermatitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | tralokinumab | Zumilokibart |
|---|---|---|
| EASI-75 | 25% vs 12.7%+12.3 vs placeboNCT031316488 other results
| —Not reported |
| IGA 0/1 with 2-point improvement | 11.6% vs 11.8%−0.2 vs placeboNCT023471762 other results
| —Not reported |
| EASI-90 | 14.5% vs 4.1%+10.4 vs placeboNCT031316485 other results
| —Not reported |
| EASI, % change | -77.8% vs -73.5%−4.3 vs placeboNCT04587453 | —Not reported |
EASI-75
- tralokinumab
- 25% vs 12.7%+12.3 vs placeboNCT03131648
8 other results
- 33.2% vs 11.4% NCT03160885
- 27.8% vs 6.4% NCT03526861
- 28.6% vs 6.4% NCT03526861
- 56% vs 35.7% NCT03363854
- 71.7% vs 56.6% NCT04587453
- 64.2% vs 50.5% NCT03761537
- 68.8% vs 55.3% NCT03761537
- 49.1% vs 36.1% NCT03562377
- Zumilokibart
- —Not reported
IGA 0/1 with 2-point improvement
- tralokinumab
- 11.6% vs 11.8%−0.2 vs placeboNCT02347176
2 other results
- 19.5% vs 11.8% NCT02347176
- 26.7% vs 11.8% NCT02347176
- Zumilokibart
- —Not reported
EASI-90
- tralokinumab
- 14.5% vs 4.1%+10.4 vs placeboNCT03131648
5 other results
- 18.3% vs 5.5% NCT03160885
- 17.5% vs 4.3% NCT03526861
- 19.4% vs 4.3% NCT03526861
- 32.9% vs 21.4% NCT03363854
- 45.3% vs 30.2% NCT04587453
- Zumilokibart
- —Not reported
EASI, % change
- tralokinumab
- -77.8% vs -73.5%−4.3 vs placeboNCT04587453
- Zumilokibart
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Zumilokibart: no structured comparison results are available for Atopic Dermatitis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. tralokinumab: 4 of 4 rows · Zumilokibart: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | tralokinumab |
|---|---|
| Dropout rate | 4.5%Tralokinumaba NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 43 more results—Tralokinumab DB NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Tralokinumab OL NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q2W NCT03131648 · Phase 3 —Q2W NCT03131648 · Phase 3 —Q4W NCT03131648 · Phase 3 —Q2W + optional TCS NCT03131648 · Phase 3 · combination 5.9%300 mg Q2W NCT03160885 · Phase 3 —Q2W NCT03160885 · Phase 3 —Q2W NCT03160885 · Phase 3 —Q4W NCT03160885 · Phase 3 —Q2W + Optional TCS NCT03160885 · Phase 3 · combination —Q2W+TCS NCT03363854 · Phase 3 · combination —Q2W+TCS NCT03363854 · Phase 3 · combination —Q2W+TCS NCT03363854 · Phase 3 · combination —Q4W+TCS NCT03363854 · Phase 3 · combination —Q2W+TCS NCT03363854 · Phase 3 · combination 7.1%Q2W+TCS NCT03363854 · Phase 3 · combination —Q2W+TCS NCT03363854 · Phase 3 · combination —Q4W+TCS NCT03363854 · Phase 3 · combination —300 mg Q4W NCT03526861 · Phase 3 6.9%300 mg Q2W NCT03526861 · Phase 3 —300 mg Q2W NCT03526861 · Phase 3 7%150 mg Q2W NCT03526861 · Phase 3 —150 mg Q2W NCT03526861 · Phase 3 —150 mg Q4W NCT03526861 · Phase 3 —300 mg Q2W NCT03526861 · Phase 3 · combination —150 Q2W NCT03526861 · Phase 3 —300 Q2W NCT03526861 · Phase 3 —150 Q2W NCT03526861 · Phase 3 —150 Q4W NCT03526861 · Phase 3 —300 Q2W NCT03526861 · Phase 3 —300 Q4W NCT03526861 · Phase 3 —300 Q2W NCT03526861 · Phase 3 · combination 31.6% NCT03587805 · Phase 3 · registry result, not featured evidence 14%Tralokinumab Subcutaneous Dosing b NCT05194540 · Phase 3 · registry result, not featured evidence —Tralokinumab+TCS Initial Treatment NCT05194540 · Phase 3 · registry result, not featured evidence · combination 0% NCT04587453 · Phase 3 · registry result, not featured evidence · combination —Safety Follow-up Period: Tralokinu NCT03761537 · Phase 3 · registry result, not featured evidence · combination —Treatment Period: Tralokinumab+TCS NCT03761537 · Phase 3 · registry result, not featured evidence · combination 6.5% NCT03562377 · Phase 2 · registry result, not featured evidence 20%Tralokinumab Dose 1 NCT02347176 · Phase 2 · registry result, not featured evidence 15.7%Tralokinumab Dose 2 NCT02347176 · Phase 2 · registry result, not featured evidence 7.7%Tralokinumab Dose 3 NCT02347176 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 0.6%Tralokinumaba NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 43 more results—Tralokinumab DB NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Tralokinumab OL NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q2W NCT03131648 · Phase 3 —Q2W NCT03131648 · Phase 3 —Q4W NCT03131648 · Phase 3 —Q2W + optional TCS NCT03131648 · Phase 3 · combination —300 mg Q2W NCT03160885 · Phase 3 —Q2W NCT03160885 · Phase 3 —Q2W NCT03160885 · Phase 3 —Q4W NCT03160885 · Phase 3 —Q2W + Optional TCS NCT03160885 · Phase 3 · combination —Q2W+TCS NCT03363854 · Phase 3 · combination —Q2W+TCS NCT03363854 · Phase 3 · combination —Q2W+TCS NCT03363854 · Phase 3 · combination —Q4W+TCS NCT03363854 · Phase 3 · combination —Q2W+TCS NCT03363854 · Phase 3 · combination —Q2W+TCS NCT03363854 · Phase 3 · combination —Q2W+TCS NCT03363854 · Phase 3 · combination —Q4W+TCS NCT03363854 · Phase 3 · combination —300 mg Q4W NCT03526861 · Phase 3 —300 mg Q2W NCT03526861 · Phase 3 —300 mg Q2W NCT03526861 · Phase 3 —150 mg Q2W NCT03526861 · Phase 3 —150 mg Q2W NCT03526861 · Phase 3 —150 mg Q4W NCT03526861 · Phase 3 —300 mg Q2W NCT03526861 · Phase 3 · combination —150 Q2W NCT03526861 · Phase 3 —300 Q2W NCT03526861 · Phase 3 —150 Q2W NCT03526861 · Phase 3 —150 Q4W NCT03526861 · Phase 3 —300 Q2W NCT03526861 · Phase 3 —300 Q4W NCT03526861 · Phase 3 —300 Q2W NCT03526861 · Phase 3 · combination 4.3% NCT03587805 · Phase 3 · registry result, not featured evidence —Tralokinumab Subcutaneous Dosing b NCT05194540 · Phase 3 · registry result, not featured evidence —Tralokinumab+TCS Initial Treatment NCT05194540 · Phase 3 · registry result, not featured evidence · combination — NCT04587453 · Phase 3 · registry result, not featured evidence · combination —Safety Follow-up Period: Tralokinu NCT03761537 · Phase 3 · registry result, not featured evidence · combination —Treatment Period: Tralokinumab+TCS NCT03761537 · Phase 3 · registry result, not featured evidence · combination — NCT03562377 · Phase 2 · registry result, not featured evidence —Tralokinumab Dose 1 NCT02347176 · Phase 2 · registry result, not featured evidence —Tralokinumab Dose 2 NCT02347176 · Phase 2 · registry result, not featured evidence —Tralokinumab Dose 3 NCT02347176 · Phase 2 · registry result, not featured evidence |
| Serious AEs | —Tralokinumaba NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 43 more results1.9%Tralokinumab DB NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 1.9%Tralokinumab OL NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 3.8%Q2W NCT03131648 · Phase 3 1.5%Q2W NCT03131648 · Phase 3 3.9%Q4W NCT03131648 · Phase 3 4.8%Q2W + optional TCS NCT03131648 · Phase 3 · combination —300 mg Q2W NCT03160885 · Phase 3 1.7%Q2W NCT03160885 · Phase 3 0%Q2W NCT03160885 · Phase 3 3.4%Q4W NCT03160885 · Phase 3 2.9%Q2W + Optional TCS NCT03160885 · Phase 3 · combination 0%Q2W+TCS NCT03363854 · Phase 3 · combination 2.1%Q2W+TCS NCT03363854 · Phase 3 · combination 4.3%Q2W+TCS NCT03363854 · Phase 3 · combination 0%Q4W+TCS NCT03363854 · Phase 3 · combination 0.8%Q2W+TCS NCT03363854 · Phase 3 · combination —Q2W+TCS NCT03363854 · Phase 3 · combination —Q2W+TCS NCT03363854 · Phase 3 · combination —Q4W+TCS NCT03363854 · Phase 3 · combination —300 mg Q4W NCT03526861 · Phase 3 —300 mg Q2W NCT03526861 · Phase 3 —300 mg Q2W NCT03526861 · Phase 3 —150 mg Q2W NCT03526861 · Phase 3 —150 mg Q2W NCT03526861 · Phase 3 —150 mg Q4W NCT03526861 · Phase 3 —300 mg Q2W NCT03526861 · Phase 3 · combination 3.1%150 Q2W NCT03526861 · Phase 3 1%300 Q2W NCT03526861 · Phase 3 0%150 Q2W NCT03526861 · Phase 3 0%150 Q4W NCT03526861 · Phase 3 0%300 Q2W NCT03526861 · Phase 3 0%300 Q4W NCT03526861 · Phase 3 3%300 Q2W NCT03526861 · Phase 3 · combination 9% NCT03587805 · Phase 3 · registry result, not featured evidence —Tralokinumab Subcutaneous Dosing b NCT05194540 · Phase 3 · registry result, not featured evidence 0%Tralokinumab+TCS Initial Treatment NCT05194540 · Phase 3 · registry result, not featured evidence · combination — NCT04587453 · Phase 3 · registry result, not featured evidence · combination 0%Safety Follow-up Period: Tralokinu NCT03761537 · Phase 3 · registry result, not featured evidence · combination 0.7%Treatment Period: Tralokinumab+TCS NCT03761537 · Phase 3 · registry result, not featured evidence · combination 2.8% NCT03562377 · Phase 2 · registry result, not featured evidence 6%Tralokinumab Dose 1 NCT02347176 · Phase 2 · registry result, not featured evidence 3.9%Tralokinumab Dose 2 NCT02347176 · Phase 2 · registry result, not featured evidence 0%Tralokinumab Dose 3 NCT02347176 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a nasopharyngitis 16.7% (placebo 7.6%) injection site reaction 6.4% (placebo 1.3%) dermatitis atopic 5.8% (placebo 5.1%) NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 29 more resultsinjection site reaction 7.9% (placebo 1.3%) nasopharyngitis 7.5% (placebo 7.6%) covid-19 0% (placebo 0%) NCT05958407 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 Q2W dermatitis atopic 25.2% (placebo 38.3%) viral upper respiratory tract infection 23.1% (placebo 20.9%) conjunctivitis 7.1% (placebo 2%) NCT03131648 · Phase 3 Q2W viral upper respiratory tract infection 20.6% (placebo 20.9%) dermatitis atopic 16.2% (placebo 38.3%) headache 8.8% (placebo 5.1%) NCT03131648 · Phase 3 Q4W viral upper respiratory tract infection 23.7% (placebo 20.9%) dermatitis atopic 18.4% (placebo 38.3%) bronchitis 9.2% (placebo 2%) NCT03131648 · Phase 3 Q2W + optional TCS viral upper respiratory tract infection 25.4% (placebo 20.9%) dermatitis atopic 21.8% (placebo 38.3%) conjunctivitis 7.3% (placebo 2%) NCT03131648 · Phase 3 · combination Q2W dermatitis atopic 16.4% (placebo 33.5%) upper respiratory tract infection 10% (placebo 8.5%) viral upper respiratory tract infection 8.3% (placebo 8.5%) NCT03160885 · Phase 3 Q2W upper respiratory tract infection 15.4% (placebo 8.5%) dermatitis atopic 14.3% (placebo 33.5%) viral upper respiratory tract infection 9.9% (placebo 8.5%) NCT03160885 · Phase 3 Q4W dermatitis atopic 15.7% (placebo 33.5%) upper respiratory tract infection 10.1% (placebo 8.5%) viral upper respiratory tract infection 6.7% (placebo 8.5%) NCT03160885 · Phase 3 Q2W + Optional TCS dermatitis atopic 20.4% (placebo 33.5%) upper respiratory tract infection 11.6% (placebo 8.5%) viral upper respiratory tract infection 10.4% (placebo 8.5%) NCT03160885 · Phase 3 · combination Q2W+TCS viral upper respiratory tract infection 19% (placebo 17.1%) dermatitis atopic 7.6% (placebo 4.9%) conjunctivitis 3.8% (placebo 2.4%) NCT03363854 · Phase 3 · combination Q2W+TCS viral upper respiratory tract infection 21.1% (placebo 17.1%) dermatitis atopic 8.4% (placebo 4.9%) headache 7.4% (placebo 2.4%) NCT03363854 · Phase 3 · combination Q2W+TCS viral upper respiratory tract infection 17.4% (placebo 17.1%) upper respiratory tract infection 10.1% (placebo 4.9%) injection site reaction 7.2% (placebo 0%) NCT03363854 · Phase 3 · combination Q4W+TCS viral upper respiratory tract infection 13% (placebo 17.1%) headache 7.2% (placebo 2.4%) injection site reaction 5.8% (placebo 0%) NCT03363854 · Phase 3 · combination Q2W+TCS viral upper respiratory tract infection 19.4% (placebo 17.1%) conjunctivitis 11.1% (placebo 2.4%) headache 8.7% (placebo 2.4%) NCT03363854 · Phase 3 · combination 150 Q2W viral upper respiratory tract infection 19.4% (placebo 8.5%) dermatitis atopic 12.2% (placebo 11.7%) upper respiratory tract infection 8.2% (placebo 4.3%) NCT03526861 · Phase 3 300 Q2W viral upper respiratory tract infection 12.4% (placebo 8.5%) upper respiratory tract infection 11.3% (placebo 4.3%) dermatitis atopic 7.2% (placebo 11.7%) NCT03526861 · Phase 3 150 Q2W pharyngitis 25% (placebo 4.3%) acne 8.3% (placebo 4.3%) acute sinusitis 8.3% (placebo 1.1%) NCT03526861 · Phase 3 150 Q4W dermatitis atopic 14.3% (placebo 11.7%) acne 7.1% (placebo 4.3%) attention deficit/hyperactivity disorder 7.1% (placebo 0%) NCT03526861 · Phase 3 300 Q2W influenza 18.2% (placebo 1.1%) upper respiratory tract infection 18.2% (placebo 4.3%) viral upper respiratory tract infection 18.2% (placebo 8.5%) NCT03526861 · Phase 3 300 Q4W bacterial vaginosis 7.7% (placebo 0%) conjunctivitis 7.7% (placebo 0%) inappropriate schedule of drug administration 7.7% (placebo 0%) NCT03526861 · Phase 3 300 Q2W viral upper respiratory tract infection 18.8% (placebo 8.5%) upper respiratory tract infection 10.7% (placebo 4.3%) dermatitis atopic 8.1% (placebo 11.7%) NCT03526861 · Phase 3 · combination nasopharyngitis 22.2% atopic dermatitis 21% covid-19 17.6% NCT03587805 · Phase 3 · registry result, not featured evidence injection site reaction 5.9% dermatitis atopic 4.4% conjunctivitis 2.9% NCT05194540 · Phase 3 · registry result, not featured evidence · combination viral upper respiratory tract infection 2.7% (placebo 1.2%) arthralgia 1.3% (placebo 0%) cholelithiasis 1.3% (placebo 0%) NCT03761537 · Phase 3 · registry result, not featured evidence · combination viral upper respiratory tract infection 26.8% (placebo 1.2%) headache 15.2% (placebo 0%) upper respiratory tract infection 7.2% (placebo 0%) NCT03761537 · Phase 3 · registry result, not featured evidence · combination dermatitis atopic 11.2% (placebo 12.1%) viral upper respiratory tract infection 9.3% (placebo 2.8%) headache 2.8% (placebo 1.9%) NCT03562377 · Phase 2 · registry result, not featured evidence nasopharyngitis 22% (placebo 11.8%) upper respiratory tract infection 10% (placebo 9.8%) dermatitis atopic 6% (placebo 7.8%) NCT02347176 · Phase 2 · registry result, not featured evidence nasopharyngitis 15.7% (placebo 11.8%) upper respiratory tract infection 11.8% (placebo 9.8%) headache 7.8% (placebo 3.9%) NCT02347176 · Phase 2 · registry result, not featured evidence nasopharyngitis 25% (placebo 11.8%) headache 7.7% (placebo 3.9%) upper respiratory tract infection 7.7% (placebo 9.8%) NCT02347176 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 41 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
tralokinumab
+ 46 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: tralokinumab's landscape · Zumilokibart's landscape